Several months back, this stock broke out with wholesale backing along with retail investor enthusiasm over several products in the pipeline with promising outlooks. Since then, .........news about ongoing trials with positive results to date. No bad news regarding any of the pipeline. IBB correction along with most of the biotech sector in normal back and fill fashion.
Retail investors in somewhat of a dilemma apparently because the stock does not rise in a linear fashion. Wholesale investors still solid holders with what reads as a $1.05 type of basis.
Summary: Same fundamentals with the exception of good news on the ongoing pipeline studies. Retail investors selling, Professionals holding. Judging from minimal during sell, we can deduce retail paring of shares and resultant price declines.
I am long this stock for the same reasons I was earlier on.
Resultant huge price increases likely with favorable pipeline results.